Evogene Ltd (NASDAQ:EVGN) saw a significant increase in short interest in July. As of July 15th, there was short interest totalling 57,300 shares, an increase of 62.3% from the June 30th total of 35,300 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 116,500 shares, the days-to-cover ratio is presently 0.5 days.
An institutional investor recently raised its position in Evogene stock. Jane Street Group LLC boosted its position in Evogene Ltd (NASDAQ:EVGN) by 153.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,000 shares of the biotechnology company’s stock after acquiring an additional 19,382 shares during the period. Jane Street Group LLC owned 0.12% of Evogene worth $38,000 at the end of the most recent quarter. 26.10% of the stock is owned by hedge funds and other institutional investors.
Evogene stock opened at $1.04 on Friday. The business’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $1.19. Evogene has a 12-month low of $0.75 and a 12-month high of $1.83. The company has a current ratio of 9.55, a quick ratio of 9.55 and a debt-to-equity ratio of 0.03.
Evogene Company Profile
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.
Read More: Backdoor Roth IRA Conversion and Strategy
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.